On Monday, Sanofi announced that it has established a production partnership with Johnson & Johnson to produce a vaccine against Johnson & Johnson's adenovirus vector in Europe.
After Johnson & Johnson's new crown pneumonia vaccine is approved, Sanofi will use its factory in Massai Tour, France to assist Johnson & Johnson in vaccine production. Sanofi said that the staff at the Masai Tour plant will be responsible for formulating and bottling Johnson & Johnson vaccines. The plant's productivity can reach about 12 million vaccine doses per month. Sanofi CEO Paul Hudson said in a statement that the cooperation "shows Sanofi's continued commitment to participate in global forces and end this crisis as soon as possible."
It is worth mentioning that according to Johnson & Johnson’s recent release of the latest test data, the vaccine is sufficient to prevent the new coronavirus after 1 dose. In contrast, the Pfizer and BioNTech vaccines and Moderna vaccines that have been approved in the United States must be injected 2 The interval between two injections is 3 to 4 weeks. In addition, Johnson & Johnson's new crown pneumonia vaccine can be stored at refrigerator temperature for 3 months, and the storage conditions do not require the harsh low-temperature freezing environment like Pfizer and BioNTech vaccines. Under the great convenience advantage, if Johnson & Johnson vaccine can realize the promise of single-dose immunization, then this vaccine will undoubtedly become a better vaccine choice.
Johnson & Johnson has previously completed a large-scale Phase 3 vaccine trial and submitted relevant data results to regulatory agencies in the United States and Europe. The US FDA's upcoming advisory committee will vote on whether to pass the emergency authorization of the vaccine. Johnson & Johnson predicts that 60 million doses of vaccine should be available in April this year.
At the end of last year, Sanofi had to postpone vaccine development due to unsatisfactory test progress. Not long before it reached a vaccine cooperation with Johnson & Johnson, Sanofi announced a partnership with Pfizer and BioNTech to assist the two companies in the production of 100 million doses of mRNA vaccines. Sanofi will provide BioNTech with infrastructure and professional production lines to help it produce more than 100 million doses of COVID-19 vaccine in Europe in 2021. The first batch of OEM vaccine products will be delivered from Sanofi's factory in Frankfurt, Germany in August. The assistance provided by Sanofi will mainly focus on the filling of drugs and packaging. In the future, it may also involve cooperation in vaccine active ingredients, including necessary logistics support and technology transfer.
The urgency of the COVID-19 pandemic and the shortage of supply capacity have spawned numerous partnerships between large pharmaceutical companies, and former competitors have turned into collaborative alliances. For example, Eli Lilly and Amgen are cooperating to produce antibody therapies to enhance Eli Lilly's supply capacity. Roche assisted in the production of Regeneron's new crown antibody drug REGN-COV2. Bayer, which has never produced a vaccine in its nearly 160-year history, also said earlier this month that it would assist in the production of CureVac's mRNA vaccine, with the goal of producing 300 million doses in 2021. Novartis will use its plant in Stein, Switzerland to assist in the production of Pfizer/Biontech's new crown vaccine.
Although Sanofi’s top priority is to advance Sanofi’s own two COVID-19 vaccine trials, Sanofi recognizes that Pfizer, BioNTech, and Johnson & Johnson face the challenge of insufficient supply in vaccine production. Sanofi said that Sanofi can cooperate with other companies in vaccine production, provided that it has appropriate manufacturing capabilities without compromising the development of other essential drugs and vaccines.
Also on Monday, Sanofi and GlaxoSmithKline announced the resumption of new crown vaccine testing. The two companies will cooperate to advance phase II clinical trials. Phase III clinical trials are expected to begin in the second quarter. The vaccine is expected to be available in the fourth quarter. Quarterly supply. In addition to this plan, Sanofi is also cooperating with Translate Bio to research an mRNA candidate vaccine, which will enter Phase 1/2 clinical trials at the end of March.
In the early stages of vaccine development, it is generally believed that Sanofi, GlaxoSmithKline and another top vaccine giant Merck will play an important role in global immunization work, but the actual progress of these companies is far lower than expected. Instead, Pfizer, Moderna, AstraZeneca, Johnson & Johnson, and Novavax are at the forefront of this year's new crown pneumonia vaccine sales list. Analysts say that the sales of each of these companies are expected to reach the potential of billions of dollars. Under the conditions of setbacks in its own vaccine product development, Sanofi chose to actively cooperate with other companies as a way to participate in the market.
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Novel self-healing material for potential application in space coatings
Novel antiviral coating to reduce the spread of COVID-19
A major investment project of 6 billion high-end new materials settled
Top 30 best-selling oncology drugs in the world in 2020
The tight supply of ethylene glycol is difficult to change
Thermoplastic polyurethane (TPU) price increase!